MedTrace Logo

A Study to Evaluate 608 in Patients with Ankylosing Spondylitis (AS)

NCT06242652 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 250

Last updated 2024-10-23

No results posted yet for this study

Summary

This study will evaluate the effect and safety of 608 in patients with AS.

Conditions

Interventions

DRUG

608 Dose A

608 subcutaneous (SC) injection.

DRUG

608 Dose B

608 subcutaneous (SC) injection.

DRUG

608 Dose C

608 subcutaneous (SC) injection.

DRUG

Adalimumab

Adalimumab subcutaneous (SC) injection.

DRUG

Placebo

Placebo subcutaneous (SC) injection.

Sponsors & Collaborators

  • Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-03-19
Primary Completion
2025-02-27
Completion
2025-06-15

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06242652 on ClinicalTrials.gov